European Pharmaceutical Review

AUGUST 14, 2023

Eli Lilly and Company has completed acquisition of two biopharmaceutical companies – Versanis Bio and Sigilon Therapeutics – and their lead assets focused on obesity and diabetes. Lilly announced the successful completion of its acquisition of clinical-stage Versanis Bio and its lead asset bimagrumab, an anti-obesity medicine.

Biopharma 86

Biopharma Leads Medicine Management 86

European Pharmaceutical Review

SEPTEMBER 4, 2023

The biopharma company will be required to seek prior approval before acquiring related products. Divest to invest: the new normal in biopharma? The post FTC order could ease biopharma competition appeared first on European Pharmaceutical Review. The FTC has settled on a proposed consent order with Amgen Inc.

Competition 79

Competition Biopharma Pharmaceutical Government 79

European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted.

Biopharma 80

Biopharma Pharmaceutical Medicine Manufacturing 80

Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA).

Biopharma 321

Biopharma Leads 321

European Pharmaceutical Review

AUGUST 21, 2023

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 trillion in the Q1 of 2023 to $3.56 trillion in Q2 2023.

Biopharma 80

Biopharma Marketing Sales Medicine 80

Pharmaceutical Commerce

APRIL 21, 2023

In this latest Harvard Business School Healthcare Alumni Association Q&A, Dr. Peter Cappelli, Professor of Management at The Wharton School and Director of Wharton’s Center for Human Resources, explains how biopharma C-suites can lead their teams through 2023’s turbulent times.

Biopharma 52

Biopharma Healthcare Healthcare Management 52

MedCity News

MARCH 25, 2024

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

Biopharma 119

Biopharma Leads Pharma 119

Pharmaceutical Technology

OCTOBER 31, 2023

Leading biopharmas are reshaping their strategies after the announcement regarding the first drugs subject to Medicare price negotiations under the Inflation Reduction Act (IRA).

Biopharma 52

Biopharma Marketing Leads 52

Pharmaceutical Technology

MAY 10, 2023

Swedish Orphan Biovitrum (Sobi) has entered into a definitive agreement to buy biopharmaceutical company CTI BioPharma in an all-cash deal valued at $1.7bn. Sobi will start a tender offer through its wholly owned indirect subsidiary to buy all outstanding CTI shares for $9.10 for each share of common stock in cash.

Biopharma 59

Biopharma Food and Drug Administration Food Medicine 59

Pharmaceutical Technology

SEPTEMBER 2, 2022

With the takeover, Novo Nordisk will also acquire etavopivat, a lead development candidate of Forma. We have the ambition to build a leading portfolio with standalone and combination treatments to tackle the complications and underlying causes of sickle cell disease.”.

Biopharma 105

Biopharma Leads Patients Pharmaceutical 105

Pharmaceutical Technology

JUNE 2, 2023

Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material.

Biopharma 52

Biopharma Manufacturing Leads Pharmaceutical 52

Pharmaceutical Technology

MAY 15, 2023

Zhejiang DTRM Biopharma and Oncore Biopharma stand in second and third positions, respectively. Exelixis is a biopharmaceutical company that focuses on the development and commercialisation of small molecules for the treatment of cancer. By means of geographic reach, Cytokinetics holds the top position.

Leads 92

Leads Biopharma Pharmaceutical Pharma 92

MedCity News

AUGUST 4, 2022

billion acquisition of Array Biopharma in 2019. Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4

Biopharma 118

Biopharma Leads Pharma 118

pharmaphorum

DECEMBER 15, 2022

Woxström, a 26-year veteran of AstraZeneca, will lead sales, marketing, and commercial operations for 30 European countries plus Canada. Skin health-focused biopharma Almirall announced a CEO shakeup early in November, with Gianfranco Nazzi stepping down “to pursue new professional opportunities”. Other biopharma hires.

Biopharma 52

Biopharma Pharma Sales Management 52

MedCity News

DECEMBER 5, 2023

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads 115

Leads FDA Biopharma Pharma 115

MedCity News

NOVEMBER 14, 2023

Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”

Leads 108

Leads Pharma Pharmaceutical Patients 108

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

Pharmaceutical Technology

MARCH 14, 2023

The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumors when activated by radiotherapy. The company is involved in designing and manufacturing nanoparticles that safely enhance radiation therapy's efficacy in cancer treatment.

Leads 72

Leads Biopharma Pharmaceutical Manufacturing 72

PharmExec

MARCH 6, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Biopharma 52

Biopharma Leads Manufacturing 52

pharmaphorum

DECEMBER 18, 2022

Uniquely positioned, traditional patient access hubs promise to simplify the process of getting patients started on therapy and offer to provide HCPs with much-needed assistance in navigating payer requirements leading up to therapy starts. However, the cumbersome hub workflow overshadows the purported gains in productivity.

Biopharma 85

Biopharma Patients Prescription Medical 85

MedCity News

NOVEMBER 27, 2022

The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.

Leads 114

Leads Biopharma Pharma 114

MedCity News

JANUARY 9, 2023

billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. AstraZeneca has committed $1.3 In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.

Leads 114

Leads Pharma Biopharma 114

MedCity News

MARCH 4, 2024

Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment. The latest Akero data build on six-month results reported in 2022.

Leads 116

Leads Biopharma Pharma 116

Pharmaceutical Technology

MAY 15, 2023

Hoffmann-La Roche is the leading patent filer of oxazole derivatives-based cancer drug compositions. Vertex Pharmaceuticals and Arbutus Biopharma are the other key patent filers of oxazole derivatives-based cancer drug compositions. The company develops drugs and diagnostics to treat major diseases.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52

MedCity News

SEPTEMBER 23, 2022

Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure.

Leads 117

Leads Pharma Pharmaceutical Biopharma 117

Pharmaceutical Technology

MAY 24, 2023

Whilst Abliva and Ambrx Biopharma stand in second and third positions, respectively. Merck 42 Unlock company profile C. Amgen develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. Menarini Industrie Farmaceutiche Riunite. By means of geographic reach, Curis holds the top position.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Pharmacology 52

MedCity News

FEBRUARY 12, 2024

FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.

FDA 114

FDA Leads Pharmaceutical Patients 114

European Pharmaceutical Review

MAY 12, 2023

Swedish Orphan Biovitrum AB (Sobi ® ) has agreed to acquire CTI BioPharma for $1.7 The biopharma companies anticipate the transaction will help to change the treatment landscape for patients with rare diseases through new, innovative and effective medicines and therapies.

Food and Drug Administration 97

Food and Drug Administration Biopharma Medicine Food 97

MedCity News

DECEMBER 22, 2022

The future towards the safer treatment of pain will come as biopharma, and investor communities appreciate the significant opportunities in supporting scientifically rigorous and clinically validated lead assets for the safer treatment of pain.

Biopharma 94

Biopharma Leads 94

MedCity News

JANUARY 24, 2023

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.

Leads 84

Leads Biopharma Pharma 84

Pharmaceutical Technology

SEPTEMBER 8, 2022

The speciality drug channel participants, including speciality pharmacies, biopharma companies, and distributors, are transforming their operations with automated and secure data systems and next-generation analytics, which will improve data collection, partner performance and strategy effectiveness.

Specialization 45

Specialization Leads Pharma Side effects 45

PharmExec

NOVEMBER 28, 2022

With biopharma sales and marketing changing faster than ever, it’s become crucial for brands to stay relevant with each new product launch. Christopher Price shares his point of view through the lens of 20 years of experience in the space.

Marketing 52

Marketing Leads Biopharma Sales 52

pharmaphorum

DECEMBER 16, 2022

I-Mab Biopharma, meanwhile, has a bispecific antibody called TJ-CD4B – which binds to both claudin 18.2 The post Second phase 3 trial extends Astellas’ lead in claudin 18.2 Other companies developing claudin 18.2-targeted targeted therapies include China’s Innovent Bio, which started dosing patients with its CD3xClaudin 18.2

Leads 59

Leads Biopharma Prospecting Patients 59

Pharmaceutical Technology

MAY 15, 2023

Seagen, formerly Seattle Genetics, develops and markets monoclonal antibody-based therapies for the treatment of cancer.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52

European Pharmaceutical Review

APRIL 2, 2024

On his appointment , Wienand, incoming CEO, Lonza shared: “I am very much looking forward to joining Lonza and leading the company into a strong future… [helping to] serve as a partner of choice for the global biopharma industry in its quest to turn breakthrough innovations into viable therapies. billion.

Biopharma 79

Biopharma Manufacturing Leads Pharmaceutical 79

PharmExec

AUGUST 17, 2023

Key Challenges for Manufacturers and How MilliporeSigma is Leading Industry-Wide Change

Biopharma 52

Biopharma Manufacturing Leads 52

Pharmaceutical Technology

MAY 8, 2023

Hoffmann-La Roche is the leading patent filer in monoclonal antibody conjugates for cancer treatment. Hoffmann-La Roche is a biotechnology company that develops drugs and diagnostics to treat major diseases.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52